US Broker Ratings

Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 46% Potential Upside Amid Robust Analyst Support

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a prominent player in the biotechnology sector, has caught the attention of investors with its promising potential upside and robust analyst support. With a market..

Universal Health Services, Inc. (UHS) Stock Analysis: A Closer Look at Its 15% Potential Upside

Universal Health Services, Inc. (NYSE: UHS), headquartered in King of Prussia, Pennsylvania, is a prominent player in the healthcare sector, specifically within the medical care facilities industry. With a market..

Moderna, Inc. (MRNA) Stock Analysis: Exploring a 9.75% Potential Downside in the Biotech Leader

Moderna, Inc. (NASDAQ: MRNA), a prominent player in the biotechnology sector, has been a focal point for investors due to its pioneering work in mRNA technology. The company, headquartered in..

HealthEquity, Inc. (HQY) Stock Analysis: A 17.81% Upside Potential with Strong Buy Ratings

Investors eyeing the healthcare sector might find HealthEquity, Inc. (NASDAQ: HQY) a compelling opportunity, especially with its robust buy ratings and promising upside potential. As a leading provider of technology-enabled..

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 72% Potential Upside Amidst Challenging Metrics

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leader in the biotechnology sector, is making waves in the healthcare industry with its innovative RNA-targeted therapies. While the company is poised for significant..

Amgen Inc. (AMGN) Investor Outlook: Analyzing the 101% Return on Equity and Market Position

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector, continues to capture investor attention with its robust market presence and impressive financial indicators. As a leader in the drug..

Exelixis, Inc. (EXEL) Stock Analysis: Exploring the 40.99% ROE and Analyst Consensus

Exelixis, Inc. (NASDAQ: EXEL), a key player in the biotechnology sector, is capturing investor attention with its robust return on equity (ROE) of 40.99%. Specializing in oncology, Exelixis is at..

Viatris Inc. (VTRS) Stock Analysis: Navigating the Healthcare Giant’s Potential Upside Amid Market Volatility

Viatris Inc. (NASDAQ: VTRS), a prominent player in the healthcare sector, is navigating a complex landscape with strategic agility. As a leading entity within the Drug Manufacturers – Specialty &..

United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 28% Potential Upside in the Healthcare Sector

For investors eyeing opportunities in the healthcare sector, United Therapeutics Corporation (NASDAQ: UTHR) presents a compelling case with its robust product portfolio and significant upside potential. Specializing in the development..

Incyte Corporation (INCY) Stock Analysis: A Look at the Biotechnology Leader’s Growth Potential

Incyte Corporation (NASDAQ: INCY), with its substantial market capitalization of $24.23 billion, stands tall in the biotechnology industry. Headquartered in Wilmington, Delaware, Incyte has carved a niche in the healthcare..

Novo Nordisk A/S (NVO) Stock Analysis: A Healthcare Giant with a 71.4% Return on Equity

Investors looking for a robust player in the healthcare sector might find Novo Nordisk A/S (NYSE: NVO) a compelling option. With its headquarters in Bagsvaerd, Denmark, Novo Nordisk is a..

Cencora, Inc. (COR) Stock Analysis: Robust Growth Potential with a 14.56% Upside

Cencora, Inc. (NYSE: COR), a stalwart in the healthcare sector, is capturing investor attention with its promising growth trajectory and compelling stock potential. Headquartered in Conshohocken, Pennsylvania, Cencora was formerly..

DaVita Inc. (DVA) Stock Analysis: Navigating a 52-Week High with Cautious Optimism

DaVita Inc. (NYSE: DVA), a leader in the healthcare sector specializing in kidney dialysis services, has recently marked a significant milestone by reaching its 52-week high, with its current stock..

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A Deep Dive into a 26.55% Potential Upside

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) stands as a compelling opportunity for investors within the dynamic healthcare sector, specifically in the niche of drug manufacturers focusing on specialty and generic medications...

Gilead Sciences, Inc. (GILD) Stock Analysis: Solid Growth with a 20.69% Upside Potential

Gilead Sciences, Inc. (NASDAQ: GILD) stands as a formidable player in the healthcare sector, specifically within the drug manufacturing industry. With a market capitalization of $161.66 billion, Gilead has carved..

Stryker Corporation (SYK) Stock Analysis: Exploring Growth Potential and Analyst Confidence in the Healthcare Giant

Stryker Corporation (NYSE: SYK) remains a formidable player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $124.86 billion, Stryker’s robust presence is felt..

Revvity, Inc. (RVTY) Stock Report: Analyzing the Healthcare Giant’s 4.10% Potential Upside

Revvity, Inc. (NYSE: RVTY), a prominent player in the healthcare sector, specifically in the diagnostics and research industry, is catching the eyes of investors with its promising 4.10% potential upside...

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Exploring a 17.68% Potential Upside

Teva Pharmaceutical Industries Limited (NYSE: TEVA), a formidable player in the global healthcare sector, continues to capture the attention of individual investors. With a market capitalization of $40.8 billion, Teva..

Abbott Laboratories (ABT) Stock Analysis: Navigating a 12% Upside Potential Amid Robust Healthcare Offerings

Abbott Laboratories (NYSE: ABT), a cornerstone of the healthcare sector, continues to draw investor attention with its expansive portfolio and strategic positioning in the medical devices industry. With a market..

Corcept Therapeutics (CORT): A Biotech Powerhouse with 18% Upside Potential

Corcept Therapeutics Incorporated (NASDAQ: CORT), a prominent player in the biotechnology sector, has captured investor attention with its remarkable potential for growth and innovation. With a market capitalization of $12.38..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds